Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
01 10 2022
Historique:
received: 20 01 2022
accepted: 11 07 2022
pubmed: 30 8 2022
medline: 5 10 2022
entrez: 29 8 2022
Statut: ppublish

Résumé

Advanced prostate cancer (aPC) in Black men was reported to present with aggressive features and to be associated with poor prognosis. Herein, we compared the cell-free DNA (cfDNA) genomic landscape of aPC in Black vs White men. Patients (pts) with aPC from 6 academic institutions and available cfDNA comprehensive genomic profiling (CGP) were included. Association between mutated genes and race was evaluated using Barnard's test and a Probabilistic Graphical Model (PGM) machine learning approach. Analysis included 743 aPC pts (217 Black, 526 White) with available cfDNA CGP. The frequency of alterations in the androgen receptor gene was significantly higher in Black vs White men (55.3% vs 35% respectively, P < .001). Additionally, alterations in EGFR, MYC, FGFR1, and CTNNB1 were present at higher frequencies in Black men. PGM analysis and Barnard's test were concordant. Findings from the largest cohort of Black men with aPC undergoing cfDNA CGP may guide further drug development in these men.

Identifiants

pubmed: 36036607
pii: 6678487
doi: 10.1093/oncolo/oyac176
pmc: PMC9526493
doi:

Substances chimiques

Cell-Free Nucleic Acids 0
Receptors, Androgen 0
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e815-e818

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press.

Références

J Clin Oncol. 2019 Feb 10;37(5):403-410
pubmed: 30576268
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526
pubmed: 32111923
Cancer Rep (Hoboken). 2021 Oct;4(5):e1340
pubmed: 33599076
EBioMedicine. 2017 Apr;18:83-93
pubmed: 28412251
Clin Cancer Res. 2022 Jan 15;28(2):318-326
pubmed: 34667026
Oncologist. 2021 Sep;26(9):751-760
pubmed: 34157173
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890

Auteurs

Raquel Zimmerman (R)

University of Utah School of Medicine, Salt Lake City, UT, USA.
Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.

Mehmet A Bilen (MA)

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Elisabeth I Heath (EI)

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

Lakshminarayanan Nandagopal (L)

University of Alabama at Birmingham, Birmingham, AL, USA.

Umang Swami (U)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Adam Kessel (A)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Ellen Jaeger (E)

Deming Department of Medicine, Section of Hematology/Oncology, Tulane University Medical School, New Orleans, LA, USA.

Sergiusz Wesolowski (S)

Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.

Edgar J Hernanadez (EJ)

Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.

Jonathan Chipman (J)

University of Utah School of Medicine, Salt Lake City, UT, USA.

Alleda Mack (A)

Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.

Deepak Ravindranathan (D)

Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.

Benjamin L Maughan (BL)

University of Utah School of Medicine, Salt Lake City, UT, USA.

Roberto Nussenzveig (R)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Mark Yandell (M)

Department of Human Genetics, University of Utah, Salt Lake City, UT, USA.

Manish Kohli (M)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Michael B Lilly (MB)

Medical University of South Carolina Hollings Cancer Center, Charleston, SC, USA.

A Oliver Sartor (AO)

Deming Department of Medicine, Section of Hematology/Oncology, Tulane University Medical School, New Orleans, LA, USA.

Neeraj Agarwal (N)

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

Pedro C Barata (PC)

Deming Department of Medicine, Section of Hematology/Oncology, Tulane University Medical School, New Orleans, LA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH